‘Nationalizing bond markets’ left central financial institutions unprepared for inflation, prime HSBC economist says

‘Nationalizing bond markets’ left central financial institutions unprepared for inflation, prime HSBC economist says


Critical Points
  • Central banking companies close to the world have hiked desire prices aggressively over the earlier calendar year in a bid to rein in soaring inflation, right after a decade of free economic conditions.
  • “Section of the issue with QE was the actuality that you’re essentially nationalizing bond marketplaces. Bond markets have a pretty very practical purpose to engage in when you have got inflation, which is they are an early warning indicator,” HSBC Senior Financial Adviser Stephen King instructed CNBC’s Steve Sedgwick.



Supply

These underperforming groups may deliver AI-electric appeal. Here’s why.
Finance

These underperforming groups may deliver AI-electric appeal. Here’s why.

ETF Edge These underperforming groups may deliver AI-electric appeal. Here’s why. Published Sat, Nov 15 202511:00 AM EST Blair Bao WATCH LIVE Source

Read More
Warren Buffett’s Berkshire Hathaway reveals new position in Alphabet
Finance

Warren Buffett’s Berkshire Hathaway reveals new position in Alphabet

Warren Buffett speaks during the Berkshire Hathaway Annual Shareholders Meeting in Omaha, Nebraska on May 3, 2025. CNBC Warren Buffett’s Berkshire Hathaway revealed a new position in Alphabet, making the Google parent the conglomerate’s 10th largest equity holding at the end of September, according to a regulatory filing. Berkshire disclosed a $4.3 billion stake in […]

Read More
Stocks making the biggest moves midday: Whirlpool, Topgolf Callaway, Nvidia, Stubhub & more
Finance

Stocks making the biggest moves midday: Whirlpool, Topgolf Callaway, Nvidia, Stubhub & more

Check out the companies making the biggest moves midday: Scholar Rock — The Cambridge, Massachusetts-based biotech jumped 23% after saying it ” completed constructive and collaborative in-person Type A meeting ” with the FDA on Wednesday for a biologics license application for apitegromab, a spinal muscular atrophy treatment. Officials from Novo Nordisk’s Catalent Indiana joined […]

Read More